Article
Oncology
A. J. M. Meijer, F. A. Diepstraten, T. Langer, L. Broer, I. K. Domingo, E. Clemens, A. G. Uitterlinden, A. C. H. de Vries, M. van Grotel, W. P. Vermeij, R. A. Ozinga, H. Binder, J. Byrne, E. van Dulmen-den Broeder, M. L. Garre, D. Grabow, P. Kaatsch, M. Kaiser, L. Kenborg, J. F. Winther, C. Rechnitzer, H. Hasle, T. Kepak, K. Kepakova, W. J. E. Tissing, A. L. F. van der Kooi, L. C. M. Kremer, J. Kruseova, S. M. F. Pluijm, C. E. Kuehni, H. J. H. van der Pal, R. Parfitt, C. Spix, A. Tillmanns, D. Deuster, P. Matulat, G. Calaminus, A. E. Hoetink, S. Elsner, J. Gebauer, R. Haupt, H. Lackner, C. Blattmann, S. J. C. M. M. Neggers, S. R. Rassekh, G. E. B. Wright, B. Brooks, A. P. Nagtegaal, B. I. Drogemoller, C. J. D. Ross, A. P. Bhavsar, A. G. Am Zehnhoff-Dinnesen, B. C. Carleton, O. Zolk, M. M. van den Heuvel-Eibrink
Summary: Genetic susceptibility plays a role in the occurrence of hearing loss after treatment, with the genetic variant rs893507 in the TCERG1L gene associated with ototoxicity in children with cancer. Replication studies in two independent cohorts confirmed this association. Modulating TCERG1L expression in cultured human cells altered cellular responses to cisplatin-induced cytokine secretion and toxicity, providing insights into the genetic and pathophysiological basis of cisplatin-induced ototoxicity.
NPJ PRECISION ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
David S. Lee, Emma Y. Travis, Susan K. Wong, Cathryn Collopy, Katrina S. McClannahan, Amanda J. Ortmann, Jason T. Rich, Patrik Pipkorn, Sidharth V. Puram, Ryan S. Jackson, Randal C. Paniello, Douglas R. Adkins, Peter Oppelt, Wade L. Thorstad, Cameron C. Wick, Jose P. Zevallos, Angela L. Mazul
Summary: This study evaluated factors associated with adherence to ototoxicity monitoring among patients with head and neck cancer treated with cisplatin and radiation therapy. A retrospective cohort study was conducted on patients enrolled in an ototoxicity monitoring program. The results showed moderately high follow-up rates for at least one post-treatment audiogram, but follow-up decreased significantly after 6 months and hearing aid utilization was low, with only 24.8% of recommended patients actually using one.
Article
Oncology
Miranda L. Camet, Anne Spence, Susan S. Hayashi, Ningying Wu, Jennifer Henry, Kara Sauerburger, Robert J. Hayashi
Summary: This study aimed to investigate the impact of cisplatin dosing and schedules on hearing loss, and found that the amount of cisplatin infused per dose is associated with hearing loss. The study suggests designing regimens that reduce the amount of cisplatin infused per dose may help reduce the risk of hearing loss.
FRONTIERS IN ONCOLOGY
(2021)
Review
Neurosciences
Pattarawadee Prayuenyong, David M. Baguley, Corne J. Kros, Peter S. Steyger
Summary: Recent studies have shown that cisplatin-induced ototoxicity in humans primarily affects the cochlea rather than the vestibule. The susceptibility of inner ear hair cells to cisplatin may be due to their intrinsic characteristics. Understanding the mechanisms of cisplatin preferential cochleotoxicity and the role of the stria vascularis could potentially lead to the development of new interventions to moderate cisplatin-associated ototoxicity.
FRONTIERS IN NEUROSCIENCE
(2021)
Article
Oncology
Mohammad Shahbazi, Xindi Zhang, Paul C. Dinh, Victoria A. Sanchez, Matthew R. Trendowski, Megan M. Shuey, Tessa Nguyen, Darren R. Feldman, David J. Vaughn, Chunkit Fung, Christian Kollmannsberger, Neil E. Martin, Lawrence H. Einhorn, Nancy J. Cox, Robert D. Frisina, Lois B. Travis, Mary Eileen Dolan
Summary: This study investigated the clinical and genetic risk factors for symmetric deterioration of speech recognition thresholds (SRT) among cancer survivors treated with cisplatin. The results suggest that self-reported health, smoking, and BMI are associated with SRT-based hearing disability (SHD).
Article
Oncology
Myriam Campbell, Csongor Kiss, Martin Zimmermann, Cecilia Riccheri, Jerzy Kowalczyk, Maria S. Felice, Milos Kuzmanovic, Gabor Kovacs, Helen Kosmidis, Alejandro Gonzalez, Ernest Bilic, Luis Castillo, Alexandra Kolenova, Janez Jazbec, Alexander Popa, Dobrin Konstantinov, Janos Kappelmayer, Tomasz Szczepanski, Michael Dworzak, Barbara Buldini, Giuseppe Gaipa, Neda Marinov, Jorge Rossi, Attila Nagy, Imre Gaspar, Jan Stary, Martin Schrappe
Summary: The International BFM study group conducted a study on pediatric ALL, evaluating MRD using FCM and the impact of early intensification and MTX dose on survival. The results showed that MRD was successfully assessed using FCM, and a dose of 2g/m2 MTX was effective in preventing relapse in non-HR pcB-ALL. Augmented IB showed no advantages over the standard IB.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Cell Biology
Tingting Dong, Xuejie Zhang, Yiqing Liu, Shan Xu, Haishuang Chang, Fengqiu Chen, Lulu Pan, Shaoru Hu, Min Wang, Min Lu
Summary: Mutations in the OPA1 gene can lead to optic atrophy and hearing impairment, and Opa1 plays a vital role in protecting against cisplatin-induced cochlear cell death by preserving mitochondrial function.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Otorhinolaryngology
Brian C. Deutsch, Cathryn Collopy, Dorina Kallogjeri, Jay F. Piccirillo
Summary: The study validated a predictive model for hearing outcomes and assessed barriers to its implementation. It found high accuracy in predicting treatment-induced hearing loss in head and neck cancer patients and suggested good calibration and discrimination, making it a valuable tool for counseling and planning follow-up care.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
(2021)
Article
Medicine, General & Internal
Ibrahim Azar, Omid Yazdanpanah, Hyejeong Jang, Adam Austin, Seongho Kim, Jie Chi, Samer Alkassis, Biplab K. Saha, Amit Chopra, Kristoffer Neu, Syed Mehdi, Hirva Mamdani
Summary: There is no significant difference in survival outcomes between cisplatin and carboplatin for the treatment of both limited-stage and extensive-stage small cell lung cancer (SCLC). The favorable toxicity profile of carboplatin and comparable overall survival support its use in clinical practice for both types of SCLC and allow for combination with novel treatment strategies in clinical trials.
Article
Neurosciences
Dongmei Tang, Xue Wang, Jingfang Wu, Yimeng Li, Cai Li, Xiangyun Qiao, Li Fan, Yutao Chen, Huanhuan Zhu, Zhiyuan Zhang, Yingzi He
Summary: Cinchonine (CN) and cinchonidine (CD) can reduce ototoxicity caused by cisplatin and may help treat cisplatin-associated hearing loss.
CNS NEUROSCIENCE & THERAPEUTICS
(2023)
Article
Oncology
Jessica Paken, Cyril D. Govender, Mershen Pillay, Birhanu T. Ayele, Vikash Sewram
Summary: Exposure to cisplatin treatment can lead to hearing loss in cervical cancer patients, especially in the high-frequency range. The study demonstrates the feasibility of recruiting and following up study participants in limited-resource environments, emphasizing the importance of a multidisciplinary approach and regular communication with participants.
Article
Pharmacology & Pharmacy
Benyu Nan, Zirui Zhao, Kanglun Jiang, Xi Gu, Huawei Li, Xinsheng Huang
Summary: In this study, it was demonstrated through computer simulation and experimental validation that Astaxanthine (AST) can reduce cisplatin-induced ototoxicity through the NRF2-mediated pathway, reducing overexpression of reactive oxygen species (ROS), improving mitochondrial dysfunction, and reducing cell apoptosis, thereby promoting cell survival.
ACTA PHARMACEUTICA SINICA B
(2022)
Review
Neurosciences
Yingru Li, Tianyang Zhang, Qiang Song, Dekun Gao, Yue Li, Huiqun Jie, Ping Huang, Guiliang Zheng, Jun Yang, Jingchun He
Summary: This article reviews the importance of cisplatin as a first-line chemotherapeutic agent in the treatment of malignant tumors, while discussing the limitations imposed by its ototoxicity and neurotoxicity. The article explores the pathways and molecular mechanisms of cisplatin trafficking into the inner ear, its toxic effects on inner ear cells, and the cascade reactions leading to cell death. Additionally, it highlights the protective mechanisms of anti-apoptosis and mitophagy activation in the inner ear, as well as the current clinical preventive measures and novel therapeutic agents for cisplatin ototoxicity. Furthermore, the article discusses possible drug targets for mitigating cisplatin-induced ototoxicity, including antioxidants, transporter protein inhibitors, cellular pathway inhibitors, combination drug delivery methods, and other promising mechanisms identified in preclinical studies. Further research is needed to evaluate the efficacy and safety of these approaches.
FRONTIERS IN CELLULAR NEUROSCIENCE
(2023)
Article
Pharmacology & Pharmacy
Evelien G. E. Hurkmans, Marije J. Klumpers, Cinzia Dello Russo, Ward De Witte, Henk-Jan Guchelaar, Hans Gelderblom, Anne-Marie Cleton-Jansen, Sita H. Vermeulen, Suzanne Kaal, Winette T. A. van der Graaf, Uta Flucke, Corrie E. M. Gidding, Hendrik W. B. Schreuder, Eveline S. J. M. de Bont, Huib N. Caron, Giovanna Gattuso, Elisabetta Schiavello, Monica Terenziani, Maura Massimino, Geoff McCowage, Sumanth Nagabushan, Anuja Limaye, Victoria Rose, Daniel Catchpoole, Andrea L. Jorgensen, Christopher Barton, Lucy Delaney, Daniel B. Hawcutt, Munir Pirmohamed, Barry Pizer, Marieke J. H. Coenen, D. Maroeska W. M. te Loo
Summary: This study aimed to identify novel genetic variants involved in platinum-induced ototoxicity. A genome-wide association study was conducted in two cohorts, and the results were combined in a meta-analysis. Variants in TSPAN5, RBBP4P5, AC010090.1, and RNU6-38P were suggestively associated with platinum-induced ototoxicity.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Qing Tang, Xianren Wang, Huan Jin, Yanjun Mi, Lingfeng Liu, Mengyuan Dong, Yibing Chen, Zhengzhi Zou
Summary: Cisplatin, an effective antitumor drug for solid malignant tumors, is known to cause ototoxicity, which manifests as progressive, bilateral, and irreversible hearing loss. The ototoxicity is primarily related to reactive oxygen species production and activation of the apoptotic pathway in cochlear tissues. Despite protective strategies being developed, systemic administration of drugs for hearing protection may weaken cisplatin's anticancer effect.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
(2021)
Review
Oncology
Remy Merkx, Jan M. Leerink, Esmee C. de Baat, Elizabeth A. M. Feijen, Wouter E. M. Kok, Annelies M. C. Mavinkurve-Groothuis, Jacqueline Loonen, Helena J. H. van der Pal, Louise Bellersen, Chris L. de Korte, Leontien C. M. Kremer, Elvira C. van Dalen, Livia Kapusta
Summary: The study reviewed the importance of echocardiographic surveillance for asymptomatic childhood cancer survivors treated with anthracyclines, with GLS showing a higher prevalence of left ventricular systolic dysfunction compared to LVEF. Risk factors include cumulative anthracycline dose and radiotherapy involving the heart region, with no safe dose identified for ALVSD.
JOURNAL OF CANCER SURVIVORSHIP
(2022)
Article
Oncology
Julianne Byrne, Irene Schmidtmann, Humayra Rashid, Oskar Hagberg, Francesca Bagnasco, Edit Bardi, Florent De Vathaire, Samir Essiaf, Jeanette Falck Winther, Eva Frey, Thorgerdur Gudmundsdottir, Riccardo Haupt, Michael M. Hawkins, Zsuzsanna Jakab, Momcilo Jankovic, Peter Kaatsch, Leontien C. M. Kremer, Claudia E. Kuehni, Arja Harila-Saari, Gill Levitt, Raoul Reulen, Cecile M. Ronckers, Milena Maule, Roderick Skinner, Eva Steliarova-Foucher, Monic Terenziani, Lorna Zadravec Zaletel, Lars Hjorth, Stanislaw Garwicz, Desiree Grabow
Summary: Over the past 60 years, late mortality of European childhood or adolescent cancer survivors has decreased, but excess mortality remains a concern. The PanCareSurFup study found significant mortality declines among European survivors, highlighting the need for long-term care for survivors.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Biology
Milanthy Pourier, Remy Merkx, Jacqueline Loonen, Alyssa van Cleef, Chris de Korte, Louise Bellersen, Livia Kapusta, Annelies Mavinkurve-Groothuis
Summary: In echocardiographic surveillance of anthracycline-treated childhood cancer survivors, left ventricular ejection fraction may not be sufficient for predicting future cardiac events, while longitudinal strain might be more sensitive. This study found a low ten-year cumulative incidence of cardiac events in these survivors, suggesting that sensitive echocardiographic measurements like longitudinal strain may be useful for tailored surveillance.
Article
Urology & Nephrology
Esmee C. M. Kooijmans, Helena J. H. van der Pal, Saskia M. F. Pluijm, Margriet van der Heiden-van der Loo, Leontien C. M. Kremer, Dorine Bresters, Eline van Dulmen den Broeder, Marry M. van den Heuvel-Eibrink, Jacqueline J. Loonen, Marloes Louwerens, Sebastian J. C. Neggers, Cecile Ronckers, Wim J. E. Tissing, Andrica C. H. de Vries, Gertjan J. L. Kaspers, Margreet A. Veening, Arend Bokenkamp
Summary: This study aimed to evaluate glomerular dysfunction among childhood cancer survivors compared to a control group. It found a higher risk of chronic kidney disease and albuminuria in survivors, and identified several risk factors associated with these conditions. Therefore, lifelong monitoring of glomerular function is necessary for these survivors.
KIDNEY INTERNATIONAL
(2022)
Article
Oncology
Judith T. Pruijssen, Joyce Wilbers, Frederick J. A. Meijer, Sjoert A. H. Pegge, Jacqueline J. Loonen, Chris L. de Korte, Johannes H. A. M. Kaanders, Hendrik H. G. Hansen
Summary: This study examined the alterations in intima-media thickness (IMT) and stiffness-related parameters in the carotid arteries of irradiated patients. The results showed increased IMT and shear wave velocity in certain segments of the irradiated carotids. These findings highlight the need for surveillance of radiation-induced vasculopathy.
RADIATION ONCOLOGY
(2022)
Article
Oncology
Esmee C. de Baat, Elizabeth A. M. Feijen, Raoul C. Reulen, Rodrigue S. Allodji, Francesca Bagnasco, Edit Bardi, Fabien N. Belle, Julianne Byrne, Elvira C. van Dalen, Ghazi Debiche, Ibrahima Diallo, Desiree Grabow, Lars Hjorth, Momcilo Jankovic, Claudia E. Kuehni, Gill Levitt, Damien Llanas, Jacqueline Loonen, Lorna Z. Zaletel, Milena M. Maule, Lucia Miligi, Helena J. H. van der Pal, Cecile M. Ronckers, Carlotta Sacerdote, Roderick Skinner, Zsuzsanna Jakab, Cristina Veres, Nadia Haddy, David L. Winter, Florent de Vathaire, Michael M. Hawkins, Leontien C. M. Kremer
Summary: This study evaluated the risk and risk factors for heart failure in childhood cancer survivors and highlighted the impact of radiation therapy and anthracycline dose on the risk. These findings may have important implications for improving current treatment protocols and surveillance guidelines.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Elizabeth A. M. Feijen, Jop C. Teepen, Eline van Dulmen-den Broeder, Marry M. van den Heuvel-Eibrink, Margriet van der Heiden-van der Loo, Helena J. H. van der Pal, Andrica C. H. de Vries, Marloes Louwerens, Dorine Bresters, Birgitta Versluys, Hanneke de Ridder, Margreet Veening, Flora E. van Leeuwen, Martha Grootenhuis, Heleen Maurice-Stam, Hanneke M. van Santen, Sebastian J. C. M. M. Neggers, Saskia Pluijm, Jaap den Hartogh, Cecile M. Ronckers, Wim J. E. Tissing, Jacqueline J. Loonen, Leontien C. M. Kremer
Summary: The Dutch Childhood Cancer Survivor Study (DCCSS) conducted a cross-sectional clinical study (LATER 2 study) to investigate the health risks of childhood cancer survivors. Physical and psychosocial health outcomes were assessed through various measurements and questionnaires, and DNA samples were extracted. The study results will fill important gaps in knowledge and contribute to improving the quality of life and care for childhood cancer survivors.
PEDIATRIC BLOOD & CANCER
(2023)
Article
Oncology
Eline Bouwman, Saskia M. F. Pluijm, Iridi Stollman, Vera Araujo-Soares, Nicole M. A. Blijlevens, Cecilia Follin, Jeanette Falck Winther, Lars Hjorth, Tomas Kepak, Katerina Kepakova, Leontien C. M. Kremer, Monica Muraca, Helena J. H. van der Pal, Carina Schneider, Anne Uyttebroeck, Gertrui Vercruysse, Roderick Skinner, Morven C. Brown, Rosella P. M. G. Hermens, Jacqueline J. Loonen
Summary: This study identified education and training of healthcare professionals (HCPs) as key opportunities to improve health behavior support (HBS) for childhood cancer survivors (CCSs). Survivorship care clinics should work towards establishing well-integrated structured care with internal and external networks, including HBS being part of routine care. Proper understanding of facilitators and barriers should lead to better survivorship care for CCSs.
Article
Oncology
Jop C. Teepen, Judith L. Kok, Elizabeth A. M. Feijen, Jacqueline J. Loonen, Marry M. van den Heuvel-Eibrink, Helena J. van der Pal, Wim J. E. Tissing, Dorine Bresters, Birgitta Versluys, Martha A. Grootenhuis, Marloes Louwerens, Sebastian J. C. M. M. Neggers, Hanneke M. van Santen, Andrica de Vries, Geert O. Janssens, Jaap G. den Hartogh, Flora E. van Leeuwen, Nynke Hollema, Nina Streefkerk, Ellen Kilsdonk, Margriet van der Heiden-van der Loo, Eline van Dulmen-den Broeder, Cecile M. Ronckers, Leontien C. M. Kremer
Summary: This study describes the design, methodology, characteristics, and data availability of the Dutch Childhood Cancer Survivor Study LATER cohort. The aim of the study is to identify the risk of and risk factors for specific health outcomes in childhood cancer survivors. The data collected from the LATER cohort will provide new insights into risk stratification for survivors and inform the development of interventions to prevent long term adverse health outcomes.
Article
Endocrinology & Metabolism
Jenneke E. van Atteveld, Demi T. C. de Winter, Vincent G. Pluimakers, Marta Fiocco, Rutger A. J. Nievelstein, Monique G. G. Hobbelink, Andrica C. H. de Vries, Jacqueline J. Loonen, Eline van Dulmen-den Broeder, Helena J. van der Pal, Saskia M. F. Pluijm, Leontien C. M. Kremer, Cecile M. Ronckers, Margriet van der Heiden-van der Loo, A. Birgitta Versluijs, Marloes Louwerens, Dorine Bresters, Hanneke M. van Santen, Daniel S. Olsson, Imo Hoefer, Sjoerd A. A. van den Berg, Jaap den Hartogh, Wim J. E. Tissing, Sebastian J. C. M. M. Neggers, Marry M. van den Heuvel-Eibrink, Dutch LATER Study Grp
Summary: This study examined the risk factors for low bone mineral density (BMD), fractures, and vertebral fractures in adult childhood cancer survivors in the Netherlands. The results showed that childhood cancer survivors have an increased risk of fractures, and factors associated with low BMD and fractures include gender, underweight, radiotherapy dose, hormone disorders, lack of physical activity, and vitamin D deficiency. The findings highlight the importance of monitoring bone health and providing interventions for endocrine disorders and vitamin deficiencies in childhood cancer survivors.
LANCET DIABETES & ENDOCRINOLOGY
(2023)
Article
Oncology
Josien G. M. Beijer, Judith L. Kok, Geert O. Janssens, Nina Streefkerk, Andrica C. H. de Vries, Cleo Slagter, John H. Maduro, Petra S. Kroon, Martha A. Grootenhuis, Eline van Dulmen-den Broeder, Jacqueline J. Loonen, Markus Wendling, Wim J. E. Tissing, Helena J. van der Pal, Marloes Louwerens, Arjan Bel, Jaap den Hartogh, Margriet van der Heiden-van der Loo, Leontien C. M. Kremer, Jop C. Teepen, Cecile M. Ronckers
Summary: The Dutch pediatric 3D-planned radiotherapy (3D-RT) study aims to understand the long-term health outcomes among children who had radiotherapy in the 3D era. This study included pediatric cancer patients diagnosed during 2000-2012, who survived at least 5 years after initial diagnosis and 2 years post external beam radiotherapy. The study will provide valuable information for follow-up care of childhood cancer survivors and future treatment protocols. Rating: 8/10.
Article
Oncology
Joyce J. M. Claessens, Adriaan Penson, Ewald M. Bronkhorst, Leontien C. M. Kremer, Eline van Dulmen-den Broeder, Margriet van der van der Loo, Wim J. E. Tissing, Helena J. H. van der Pal, Nicole M. A. Blijlevens, Marry M. van den Heuvel-eibrink, A. Birgitta Versluys, Dorine Bresters, Cecile M. Ronckers, Iris Walraven, Catharina C. M. Beerendonk, Jacqueline J. J. Loonen, Dutch LATER Study Grp
Summary: This study evaluates the desire for children in male childhood cancer survivors compared to their male siblings. It finds that the percentage of men with a desire for children is significantly lower among survivors, and they are five times more likely to have an unfulfilled desire for children compared to their siblings. This insight is important for understanding the needs and challenges of survivors regarding family planning and fertility issues.
Meeting Abstract
Oncology
Eline Bouwman, Adriaan Penson, Maud De Valk, Selina Van den Oever, Helena Van der Pal, Eline Van Dulmen-Den Broeder, Nicole Blijlevens, Dorine Bresters, E. (Lieke) Feijen, Marry Van den Heuvel-Eibrink, Margriet Van der Heiden-Van Der Loo, Cecile Ronckers, Jop Teepen, Wim Tissing, Birgitta Versluys, Leontien Kremer, Saskia Pluijm, Jacqueline Loonen
PEDIATRIC BLOOD & CANCER
(2022)
Meeting Abstract
Oncology
Joyce Claessens, Adriaan Penson, Ewald Bronkhorst, Leontien Kremer, Eline Van Dulmen-Den Broeder, Margriet Van der Heiden-Van Der Loo, Wim Tissing, Helena Van der Pal, Nicole Blijlevens, Marry Van den Heuvel-Eibrink, Birgitta Versluys, Dorine Bresters, Cecile Ronckers, Iris Wlraven, Catharina Beerendonk, Jacqueline Loonen
PEDIATRIC BLOOD & CANCER
(2022)
Meeting Abstract
Oncology
Demi De Winter, Jenneke Van Atteveld, Vincent Pluimakers, Marta Fiocco, Rutger-Jan Nievelstein, Monique Hobbelink, Andrica De Vries, Jacqueline Loonen, Eline Van Dulmen-Den Broeder, Helena Van der Pal, Saskia Pluijm, Leontien Kremer, Cecile Ronckers, Margriet Van der Heiden-Van Der Loo, A. Birgitta Versluijs, Marloes Louwerens, Dorine Bresters, Hanneke Van Santen, Daniel Olsson, Imo Hoefer, Sjoerd Van den Berg, Jaap Den Hartogh, Wim Tissing, Sebastian Neggers, Marry Van den Heuvel-Eibrink
PEDIATRIC BLOOD & CANCER
(2022)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)
